Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp
Randomized, Multi-Center, Evaluator-Blind, Vehicle-Controlled Study to Evaluate Efficacy and Safety of Reformulated Levulan Kerastick Plus Photodynamic Therapy (PDT) for Field-Directed Treatment in Patients With Actinic Keratosis (AK) of Face and (Bald) Scalp
In the register
This trial is not attached to a programme in the register yet. Unattached trials are kept on purpose: they are where new programmes turn up first.
What the registry records
- Status
- Recruiting
- Declared phase
- Phase 3
- Sponsor
- Sun Pharmaceutical Industries, Inc.
- Participants (registry)
- 160
- Start
- November 2025
- Primary completion
- January 2027 (planned)
- Study completion
- April 2027 (planned)
- Last registry update
- April 2026
- Countries
- United States
Conditions studied: Actinic Keratosis
Interventions: Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%, Vehicle containing excipients only (VEH) without active ingredient, Blue Light Photodynamic Therapy Illuminator device, BLU-U® model 4170E
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.